RxDoctor Payments Data

Shivani Shah, MD

Nephrology · Naperville, ILNPI 1982837779

Payments from drug & device makers

$1,272in general payments, 2019–2025

Across 43 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$524
  • Otsuka America Pharmaceutical, Inc.$304
  • Vioptix Inc$111
  • AstraZeneca$65
  • Ardelyx, Inc.$50
  • Boehringer Ingelheim$44
  • plus $175 from 6 others

What the payments were for

  • Food & beverage$1,15591%
  • Education$1179%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,272 in reported general payments places this provider in the 60th percentile of 524 nephrology providers in Illinois.

See all nephrology providers in Illinois

Medicare billing

Part B allowed, 2024
$200,982
Medicare patients
337
Services billed
3,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol60$57,800
XphozahTenapanor Hcl21$57,206
VelphoroSucroferric Oxyhydroxide17$47,872
JardianceEmpagliflozin42$28,034
VeltassaPatiromer Calcium Sorbitex25$27,539
Sevelamer Carbonate20$4,365
Midodrine Hcl16$1,615
Calcium Acetate26$1,466
Carvedilol91$1,171
Hydralazine Hcl38$972
Nifedipine ErNifedipine31$908
Bumetanide24$853
Losartan Potassium71$666
Amlodipine Besylate68$561
Calcitriol59$455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$65$57,80060 claims
Boehringer IngelheimJardiance$44$28,03442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 524 nephrology providers in Illinois.

Other nephrology in Naperville

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →